Scholar Rock (NASDAQ:SRRK) Director Michael Gilman Sells 2,544 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Michael Gilman sold 2,544 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total value of $137,045.28. Following the completion of the transaction, the director owned 59,511 shares in the company, valued at $3,205,857.57. This trade represents a 4.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Up 0.1%

Scholar Rock stock opened at $55.40 on Tuesday. Scholar Rock Holding Corporation has a twelve month low of $27.07 and a twelve month high of $56.54. The stock has a 50 day moving average of $48.59 and a two-hundred day moving average of $46.67. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $6.64 billion, a price-to-earnings ratio of -15.44 and a beta of 0.67.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter last year, the business earned ($0.67) earnings per share. As a group, research analysts expect that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current year.

Hedge Funds Weigh In On Scholar Rock

Institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC lifted its stake in shares of Scholar Rock by 609.3% in the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after purchasing an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Scholar Rock by 12.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after buying an additional 5,831 shares during the period. Millennium Management LLC grew its position in Scholar Rock by 37.4% during the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after buying an additional 54,555 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Scholar Rock by 25.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock valued at $5,460,000 after buying an additional 34,594 shares in the last quarter. Finally, Strs Ohio purchased a new position in Scholar Rock in the first quarter valued at about $77,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. JPMorgan Chase & Co. raised their target price on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Wedbush increased their price target on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a report on Wednesday, April 1st. Finally, Barclays raised their price objective on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Scholar Rock presently has an average rating of “Buy” and an average price target of $56.00.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).